West Pharmaceutical Services Beneish M-Score Historical Data
The historical data trend for West Pharmaceutical Services's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
West Pharmaceutical Services Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Beneish M-Score |
|
|
|
|
|
|
-2.60 |
-2.57 |
-2.17 |
-2.45 |
-2.71 |
|
West Pharmaceutical Services Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Beneish M-Score |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-2.45 |
-2.46 |
-2.51 |
-2.64 |
-2.71 |
Competitive Comparison
For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
West Pharmaceutical Services Beneish M-Score Distribution
For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where West Pharmaceutical Services's Beneish M-Score falls into.
West Pharmaceutical Services Beneish M-Score Calculation
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of West Pharmaceutical Services for today is based on a combination of the following eight different indices:
| M | = | -4.84 | + | 0.92 * DSRI | + | 0.528 * GMI | + | 0.404 * AQI | + | 0.892 * SGI | + | 0.115 * DEPI |
| = | -4.84 | + | 0.92 * 0.9876 | + | 0.528 * 1.0281 | + | 0.404 * 0.8271 | + | 0.892 * 1.0218 | + | 0.115 * 1.0476 |
| - | 0.172 * SGAI | + | 4.679 * TATA | - | 0.327 * LVGI |
| - | 0.172 * 1.0914 | + | 4.679 * -0.040397 | - | 0.327 * 0.9565 |
| = | -2.71 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
| This Year (Dec23) TTM: | Last Year (Dec22) TTM: |
Total Receivables was $512 Mil.
Revenue was 732 + 747.4 + 753.8 + 716.6 = $2,950 Mil.
Gross Profit was 278.2 + 288.3 + 291.4 + 271.3 = $1,129 Mil.
Total Current Assets was $1,936 Mil.
Total Assets was $3,830 Mil.
Property, Plant and Equipment(Net PPE) was $1,513 Mil.
Depreciation, Depletion and Amortization(DDA) was $137 Mil.
Selling, General, & Admin. Expense(SGA) was $353 Mil.
Total Current Liabilities was $672 Mil.
Long-Term Debt & Capital Lease Obligation was $157 Mil.
Net Income was 137 + 161.3 + 155.1 + 140 = $593 Mil.
Non Operating Income was -9.8 + -1.8 + -3.9 + -12.9 = $-28 Mil.
Cash Flow from Operations was 239.1 + 230.1 + 169.2 + 138.1 = $777 Mil.
|
Total Receivables was $507 Mil.
Revenue was 708.7 + 686.9 + 771.3 + 720 = $2,887 Mil.
Gross Profit was 262.1 + 268 + 321.5 + 284.6 = $1,136 Mil.
Total Current Assets was $1,920 Mil.
Total Assets was $3,617 Mil.
Property, Plant and Equipment(Net PPE) was $1,263 Mil.
Depreciation, Depletion and Amortization(DDA) was $121 Mil.
Selling, General, & Admin. Expense(SGA) was $317 Mil.
Total Current Liabilities was $519 Mil.
Long-Term Debt & Capital Lease Obligation was $300 Mil.
|
1. DSRI = Days Sales in Receivables Index
Measured as the ratio of Revenue in Total Receivables in year t to year t-1.
A large increase in DSR could be indicative of revenue inflation.
| DSRI | = | (Receivables_t / Revenue_t) | / | (Receivables_t-1 / Revenue_t-1) |
| = | (512 / 2949.8) | / | (507.4 / 2886.9) |
| = | 0.173571 | / | 0.175759 |
| | = | 0.9876 |
2. GMI = Gross Margin Index
Measured as the ratio of gross margin in year t-1 to gross margin in year t.
Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.
| GMI | = | GrossMargin_t-1 | / | GrossMargin_t |
| = | (GrossProfit_t-1 / Revenue_t-1) | / | (GrossProfit_t / Revenue_t) |
| = | (1136.2 / 2886.9) | / | (1129.2 / 2949.8) |
| = | 0.393571 | / | 0.382806 |
| | = | 1.0281 |
3. AQI = Asset Quality Index
AQI is the ratio of asset quality in year t to year t-1.
Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.
| AQI | = | (1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) | / | (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1) |
| = | (1 - (1936.4 + 1512.5) / 3829.5) | / | (1 - (1919.5 + 1262.7) / 3616.8) |
| = | 0.099386 | / | 0.120161 |
| | = | 0.8271 |
4. SGI = Sales Growth Index
Ratio of Revenue in year t to sales in year t-1.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
| SGI | = | Sales_t | / | Sales_t-1 |
| = | Revenue_t | / | Revenue_t-1 |
| = | 2949.8 | / | 2886.9 |
| | = | 1.0218 |
5. DEPI = Depreciation Index
Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
| DEPI | = | (Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) | / | (Depreciation_t / (Depreciaton_t + PPE_t)) |
| = | (120.6 / (120.6 + 1262.7)) | / | (137.3 / (137.3 + 1512.5)) |
| = | 0.087183 | / | 0.083222 |
| | = | 1.0476 |
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.
SGA expenses index > 1 means that the company is becoming less efficient in generate sales.
| SGAI | = | (SGA_t / Sales_t) | / | (SGA_t-1 /Sales_t-1) |
| = | (353.4 / 2949.8) | / | (316.9 / 2886.9) |
| = | 0.119805 | / | 0.109772 |
| | = | 1.0914 |
7. LVGI = Leverage Index
The ratio of total debt to Total Assets in year t relative to yeat t-1.
An LVGI > 1 indicates an increase in leverage
| LVGI | = | ((LTD_t + CurrentLiabilities_t) / TotalAssets_t) | / | ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1) |
| = | ((157.3 + 671.8) / 3829.5) | / | ((299.7 + 519) / 3616.8) |
| = | 0.216503 | / | 0.22636 |
| | = | 0.9565 |
8. TATA = Total Accruals to Total Assets
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
| TATA | = | (IncomefromContinuingOperations_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t |
| = | (NetIncome_t - NonOperatingIncome_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t |
| = | (593.4 - -28.4 | - | 776.5) | / | 3829.5 |
| | = | -0.040397 |
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
West Pharmaceutical Services has a M-score of -2.71 suggests that the company is unlikely to be a manipulator.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
WST has been successfully added to your